Results for: Subcutaneous Injection
Find the latest Subcutaneous Injection tenders from different organizations. SigmaTenders helps you participate in these online e-Procurement tenders. We provide access to tender details, BOQs, and technical bids, along with bidding support for Subcutaneous Injection e-tenders. Stay informed with daily email alerts and comprehensive coverage across government websites, GeM, and e-Procurement portals.
Recombinant dna origin monocomponent insulin lispro 100iu/ml 3ml solution for injection in a pre-filled pen for subcutaneous use (junior)
For complete deion and other details, please refer to tender
Insulin degludec / insulin aspart (r-dna origin) solution for subcutaneous injection. 1ml of the solution contains 100 units insulin degludec and insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56mg salt-free anhydrous insulin degludec and 1.05mg salt-free anhydrous insulin aspart in 3ml penfill cartridge.
For complete deion and other details, please refer to tender
π Procurement Opportunity for Insulin Degludec and Insulin Aspart Solutions π The Ministry of Railways, specifically the Central Government Ministry/Department, is seeking bids for the supply of Insulin Degludec and Insulin Aspart solutions. The solution provided in a 3ml Penfill Cartridge contains 100 units of Insulin Degludec and Insulin Aspart, with 70% being soluble Insulin Degludec and 30% soluble Insulin Aspart, equivalent to 2.56mg and 1.05mg of salt-free anhydrous Insulin Degludec and Insulin Aspart, respectively. π Bid Submission Deadline: May 30, 2024, 10:30 AM Interested bidders are requested to submit their proposals by the specified deadline, ensuring they meet all the technical and financial requirements as outlined in the tender document. Keywords: Insulin Degludec, Insulin Aspart, Insulin Solution, Procurement, Ministry of Railways, Central Government, Diabetes Care, Tender, Bid Submission
Insulin degludec / insulin aspart (r-dna origin) solution for subcutaneous injection. 1ml of the solution contains 100 units insulin degludec and insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56mg salt-free anhydrous insulin degludec and 1.05mg salt-free anhydrous insulin aspart in 3ml penfill cartridge.
For complete deion and other details, please refer to tender
Insulin degludec / insulin aspart (r-dna origin) solution for subcutaneous injection. 1ml of the solution contains 100 units insulin degludec and insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56mg salt-free anhydrous insulin degludec and 1.05mg salt-free anhydrous insulin aspart in 3ml penfill cartridge.
For complete deion and other details, please refer to tender
π Procurement Opportunity for Insulin Degludec and Insulin Aspart Solutions π The Ministry of Railways, specifically the Central Government Ministry/Department, is seeking bids for the supply of Insulin Degludec and Insulin Aspart solutions. The solution provided in a 3ml Penfill Cartridge contains 100 units of Insulin Degludec and Insulin Aspart, with 70% being soluble Insulin Degludec and 30% soluble Insulin Aspart, equivalent to 2.56mg and 1.05mg of salt-free anhydrous Insulin Degludec and Insulin Aspart, respectively. π Bid Submission Deadline: April 15, 2024, 10:30 AM Interested bidders are requested to submit their proposals by the specified deadline, ensuring they meet all the technical and financial requirements as outlined in the tender document. Keywords: Insulin Degludec, Insulin Aspart, Insulin Solution, Medical Tender, Ministry of Railways, Central Government, Diabetes Care, Bid Submission
Insulin degludec/insulin aspart (r-dna origin) solution for subcutaneous injection. 1 ml of the solution contains 100 units insulin degludec & insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56 mg salt-free anhydrous insulin degludec and 1.05 mg salt-free anhydrous insulin aspart in 3 ml prefilled pen
For complete deion and other details, please refer to tender
Insulin degludec/insulin aspart (r-dna origin) solution for subcutaneous injection. 1 ml of the solution contains 100 units insulin degludec & insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56 mg salt-free anhydrous insulin degludec and 1.05 mg salt-free anhydrous insulin aspart in 3 ml prefilled pen
For complete deion and other details, please refer to tender
Insulin degludec/insulin aspart (r-dna origin) solution for subcutaneous injection. 1 ml of the solution contains 100 units insulin degludec & insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56 mg salt-free anhydrous insulin degludec and 1.05 mg salt free anhydrous insulin aspart in 3 ml prefilled pen
For complete deion and other details, please refer to tender
Insulin degludec/insulin aspart (r-dna origin) solution for subcutaneous injection. 1 ml of the solution contains 100 units insulin degludec & insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56 mg salt-free anhydrous insulin degludec and 1.05 mg salt-free anhydrous insulin aspart in 3 ml prefilled pen
For complete deion and other details, please refer to tender
Insulin degludec/insulin aspart (r-dna origin) solution for subcutaneous injection. 1 ml of the solution contains 100 units insulin degludec & insulin aspart (70 percent soluble insulin degludec and 30 percent soluble insulin aspart) equivalent to 2.56 mg salt-free anhydrous insulin degludec and 1.05 mg salt-free anhydrous insulin aspart in 3 ml prefilled pen
For complete deion and other details, please refer to tender
Supply of srph031229-monocomponent biosynthetic r-dna insulin solution for injection in 3 ml cartridge for subcutaneous use 70 percent insulin degludec/30 percent insulin aspart penfill 100 units per ml.
For complete deion and other details, please refer to tender
π Urgent Tender for Insulin Cartridges ππ« The Ministry of Railways, under the Central Government, invites tenders for the supply of Monocomponent Biosynthetic R-DNA Insulin Solution for injection in 3 ml cartridges for subcutaneous use. The insulin composition is 70% Insulin Degludec and 30% Insulin Aspart, with a total of 100 units per ml. π Tender Submission Deadline: May 29, 2024, 2:30 PM This tender is for complete deionized water (DI) and all other specifications as detailed in the tender document. Interested bidders must submit their proposals by the stipulated deadline, with no tender fee or earnest money deposit (EMD) required. Keywords: Insulin Cartridges, Ministry of Railways, Central Government, Tender, Biosynthetic R-DNA Insulin, Insulin Degludec, Insulin Aspart, Subcutaneous Use, Procurement, Medical Supplies
Need support responding to this opportunity?
Get matched through GetSaarthi for documentation, proposal preparation, compliance readiness, and execution support.
Get Opportunity Matching Supportof your Industry type